New CMV prevention drug could be safer for kidney transplant patients

NCT ID NCT07266467

Recruiting now Prevention Sponsor: First Affiliated Hospital Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new drug called leymovir to the standard drug valganciclovir for preventing cytomegalovirus (CMV) infection in 290 Chinese kidney transplant recipients. Leymovir targets a different part of the virus, which may reduce side effects like bone marrow suppression and kidney damage. The goal is to see if leymovir is as effective and safer than the current treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir
What this could lead to: If successful, leymovir could offer a safer alternative to current CMV drugs, with fewer side effects like low white blood cell counts and less kidney strain.
What could go wrong: This is a phase 4 trial focused on Chinese patients, so results may not apply to other populations. The drug may still cause unexpected side effects or prove less effective than hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT

Contacts and locations

Locations

The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.